Neuroleptics are considered the mainstay for symptomatic treatment of delirium, and haloperidol is frequently the preferred drug because it is less sedating than phenothiazines and has a low incidence of anticholinergic, hypotensive, respiratory, and cardiotoxic side effects.
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Well-characterized adverse events of haloperidol and other antipsychotics include extrapyramidal effects and neuroleptic malignant syndrome. Here, we present the case of a hematopoietic stem cell transplant (SCT) patient with acute, severe, life-threatening hypoglycemia associated with haloperidol. To our knowledge, this is only the second report in the literature describing a severe hypoglycemic reaction with haloperidol. 2 This African-American male was diagnosed with chronic lymphocytic leukemia (CLL) at age 47 years. Over the next 6 years, he was treated with multiple rounds of chemotherapy and/or monoclonal antibodies. At age 53 years, the patient received nonmyeloablative conditioning with fludarabine (total of 90 mg/m 2 ) and total body irradiation (200 cG) followed by an HLA-matched unrelated donor peripheral blood SCT (22.06 Â 10 6 CD34 þ cells/kg). His prior medical history was also remarkable for chronic hepatitis C (genotype 1A) that failed eradication therapy with interferon and ribavirin, and liver biopsy at the time of transplant revealed chronic hepatitis with minimal activity and portal to periportal fibrosis, consistent with hepatitis C-induced disease (grade 1, stages 1 and 2; Batts and Ludwig 3 ). There was no history of an endocrine disorder. The post transplant course was complicated by repeated CMV reactivations as well as by biopsy-proven acute graft-versus-host-disease (GVHD) involving the GI tract (day þ 38) and the skin (day þ 85) that initially responded to steroid therapy. However, steroid-refractory chronic GVHD developed, requiring treatment with various topical and systemic immunosuppressive agents. At 11 months after transplant, the patient was hospitalized for pneumonia due to Respiratory syncytial virus, Nocardia, and Aspergillus fumigatus, requiring temporary mechanical ventilation. His further hospital course was complicated by profound steroid-induced myopathy, severe chronic skin GVHD, tacrolimus-associated hemolytic uremic syndrome, and two self-limiting episodes of altered mental status changes, for which no medical cause could be found. On day þ 417, he developed symptoms consistent with delirium with visual and auditory hallucinations, agitation, and insomnia. At that time, the patient was on multiple chronic medications including prednisone (90 mg p.o. every other day), mycophenolate mofetil (1250 mg p.o. every 12 h), caspofungin (50 mg, intravenous (i.v.) daily), trimethoprim/sulfamethoxazole (3 double-strength tablets every 12 h), valgancyclovir (900 mg p.o. once daily), extended-release oxycodone (20 mg p.o. twice daily), pantoprazole (40 mg p.o. daily), furosemide (20 mg p.o. daily), senna, multivitamins, and topical sodium fluoride and hydrocortisone. Extracorporeal photophoresis was being performed twice a week. Antipsychotic therapy was attempted with quetiapine for 7 days and then olanzapine for 3 days, but the symptoms worsened, and he became increasingly belligerent. On day þ 428, the patient was treated with haloperidol 5 mg intramuscularly (i.m.); over the next 17 h, he received an additional 15 mg of haloperidol in doses of 2-5 mg i.m. because of poor control of agitation. The patient developed extrapyramidal symptoms, and diphenhydramine (a total of 50 mg i.v.), benztropine (1 mg i.v.), and lorazepam (a total of 3 mg i.v.) were administered.
At 18 h after the first dose of haloperidol, a 0300 h routine blood sample revealed a serum glucose of 37 mg/dl (2.05 mmol/l) with other routine lab values at that time being essentially normal. The patient was immediately treated with 25 ml of 50% glucose. However, the serum glucose dropped further to 25 mg/dl (1.39 mmol/l) 21 h after first dose of haloperidol. At this time, the patient was barely arousable; no seizures were observed. He was treated with repeated administrations of intravenous and oral glucose, and haloperidol was discontinued. The patient's serum glucose normalized within 1 day, and his mental status markedly improved and remained stable thereafter.
In addition to antihyperglycemics, 4,5 a number of other drugs have been associated with hypoglycemia. 6, 7 In our case, the first-time use of haloperidol in this patient was temporally associated with the development of severe hypoglycemia. Daily serum glucose levels were routinely checked in this patient, and normal or elevated levels were noted prior to the use of haloperidol as well as after the drug was discontinued, making a causal relationship between the hypoglycemia and haloperidol most likely. Our review of the literature revealed only one report of a severe hypoglycemic reaction with haloperidol. 2 In that report, severe hypoglycemia was noted after 6 days of haloperidol therapy for agitated depression in a 77-year-old woman. At 48 h after discontinuation of haloperidol, hypoglycemia resolved.from our patient. Insulin and c-peptide levels were undetectable in the sample drawn at 0300 h, that is, prior to the serum glucose nadir, but both were present at levels expected in healthy normoglycemic patients when the serum glucose reached its lowest value of 25 mg/dl 3 h later (2.9 mIU/ml and 1.5 ng/ml, respectively).
Importantly, all of the drugs with which the patient was treated were chronic medications, and none of these had been started within 3 weeks prior to the hypoglycemic event. From the pre-existing medications, only trimethoprim/sulfamethoxazole, which had been administered to this patient for more than 3 months at relatively high doses (up to 8 double-strength tablets per day) for treatment of Nocardiosis has been associated with hypoglycemic reactions. 4, 7 As a potential mechanism, it has been suggested that sulfamethoxazole may enhance insulin secretion by binding to pancreatic islet tissue. 4 The relatively increased levels of insulin and c-peptide in our patient would certainly be consistent with an insulin-release mechanism. By comparison, the mechanism by which haloperidol might cause hypoglycemia is not understood. Whereas one study demonstrated that haloperidol inhibited glucose-stimulated insulin release from rat pancreatic beta cells in vitro, 8 another study provided evidence that haloperidol inhibits the ATP-sensitive potassium channel in mouse pancreatic beta cells. 9 Closure of this channel depolarizes the plasma membrane and allows opening of voltage-dependent calcium channels and a rapid influx of Ca 2 þ , a key step by which glucose regulates insulin exocytosis from primed secretory vesicles. 10 However, since the IC 50 for inhibition of the ATP-sensitive potassium channel is one order of magnitude higher than peak plasma concentrations in haloperidol-treated patients, it is unclear whether this inhibitory effect of haloperidol is of clinical relevance. 9 Nevertheless, the observation by Kojak Jr et al.
2 of high levels of insulin during haloperidol-associated hypoglycemia may point to a glucose-sensitizing mechanism of haloperidol similar to sulfamethoxazole, and it is intriguing to speculate that trimethoprim/sulfamethoxazole might have contributed to the haloperidol-associated hypoglycemia in our patient, for example, by interaction with blood glucose sensing by the beta cell.
In summary, our case suggests that haloperidol can be associated with severe, life-threatening hypoglycemia, indicating that hematopoietic SCT patients on haloperidol should be closely observed for development of hypoglycemic symptoms. 
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